Master Alliance Provisions Guide (MAPGuide)

Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement

  • Protecting & sharing information | Publication of Results

15. General

15.08. Publication

Licensees grants to AstraZeneca the rights to review and scientific/technology publications or scientific presentation proposed related to the Exploitation of the Licensed Product as early as possible, before the intended delivery for publication. AstraZeneca shall provide Licensees with its response to any request within thirty (30) calendar days. No publication shall be made by Licensees without the revision by AstraZeneca and Head Licensor, and such review cannot be unreasonably withheld or delayed.

In case AstraZeneca informs Licensees that the publication contains confidential information, Licensees shall exclude all such confidential information from the publication. In case the publication contains patentable information, Licensees will delay the publication for an additional period of ninety (90) days (or more, if mutually agreed between the Parties) with the purpose of preparing and filing the appropriate patents. The contribution of each party, if that is the case, shall be noticed in all publications or presentation as acknowledgement or co–authorship, as the case may be. For purposes of clarification, the Head Licensor and AstraZeneca shall retain any rights to make presentations and scientific publications related to the Exploitation of the Licensed Product, provided that they do not reveal any Confidential Information of Licensees without their prior approval, and provided that the contribution of each party, as the case may be, shall be noticed in all publications or presentation by acknowledgement or by co–authorship, as may be appropriate.